Skip to main
SLDB
SLDB logo

Solid Biosciences (SLDB) Stock Forecast & Price Target

Solid Biosciences (SLDB) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 58%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Solid Biosciences Inc. is demonstrating promising advancements in its clinical pipeline for treating Duchenne muscular dystrophy (DMD), highlighted by favorable reductions in clinical biomarkers of muscle damage, indicating improved muscle integrity in patients. Initial data from the INSPIRE DUCHENNE study reveals strong results in vector transduction and microdystrophin expression, alongside potential cardiac benefits, enhancing the company's therapeutic prospects. Furthermore, the SGT-003 treatment exhibits a favorable safety profile with minimal adverse events reported, reinforcing the company's capability to deliver effective and safe therapies for severe neuromuscular diseases.

Bears say

Solid Biosciences Inc. faces a negative outlook primarily due to the regulatory uncertainties surrounding its lead product, SGT-003, for the treatment of Duchenne muscular dystrophy (DMD); without regulatory approval, the company’s risk-adjusted financial projections could be significantly downgraded. Additionally, the company's potential sales of SGT-003 may be jeopardized if it fails to develop adequate manufacturing capacity, which could limit its ability to meet market demand. Overall, these factors create substantial risks that could hinder the company's growth and financial stability moving forward.

Solid Biosciences (SLDB) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 58% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solid Biosciences (SLDB) Forecast

Analysts have given Solid Biosciences (SLDB) a Buy based on their latest research and market trends.

According to 12 analysts, Solid Biosciences (SLDB) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solid Biosciences (SLDB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.